RUNX1 and metabolic dysfunction-associated steatohepatitis: In order to add new knowledge about the role of RUNX1 in hepatic steatosis, we then subclassified our patients with MO and NAFLD into SS (n = 24) and NASH (n = 17) (Table 1).